Abnormal localization and accumulation of FLT3-ITD, a mutant receptor tyrosine kinase involved in leukemogenesis

Cells Tissues Organs

Volumn 188, Issue 1-2, 2008, Pages 225-235

  Koch, Sina ^a   Jacobi, Angela ^a   Ryser, Martin ^a   Ehninger, Gerhard ^a   Thiede, Christian ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Acute myeloid leukemia; FLT3 ITD; Receptor tyrosine kinase; Subcellular localization

Indexed keywords

CD135 ANTIGEN; FLT3 LIGAND; PLATELET DERIVED GROWTH FACTOR; PROTEIN FLT3 ITD; PROTEIN TYROSINE KINASE; TYROSINE KINASE RECEPTOR;

ANIMAL CELL; CELL MEMBRANE; CELL SURFACE; CELLULAR DISTRIBUTION; CONFERENCE PAPER; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; GOLGI COMPLEX; IMMUNOFLUORESCENCE; LEUKEMOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

ANIMALS; CELL MEMBRANE; CELL NUCLEUS; CERCOPITHECUS AETHIOPS; COS CELLS; ENDOPLASMIC RETICULUM; FMS-LIKE TYROSINE KINASE 3; GOLGI APPARATUS; HUMANS; LEUKEMIA; MUTANT PROTEINS; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; RETROVIRIDAE; TRANSDUCTION, GENETIC;

EID: 46949103843     PISSN: 14226405     EISSN: None     Source Type: Journal    
DOI: 10.1159/000118788     Document Type: Conference Paper

References (38)

1. Antonescu, C.R., G. Sommer, L. Sarran, S.J. Tschernyavsky, E. Riedel, J.M. Woodruff, M. Robson, R. Maki, M.F. Brennan, M. Ladanyi, R.P. Dematteo, P. Besmer (2003) Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 9: 3329-3337.
2. Blume-Jensen, P., T. Hunter (2001) Oncogenic kinase signalling. Nature 411: 355-365.
3. Choudhary, C., J. Schwable, C. Brandts, L. Tickenbrock, B. Sargin, T. Kindler, T. Fischer, W.E. Berdel, C. Muller-Tidow, H. Serve (2005) AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood 106: 265-273.
4. Clarke, I.D., P.B. Dirks (2003) A human brain tumor-derived PDGFR-α deletion mutant is transforming. Oncogene 22: 722-733.
5. Cosset, F.L., Y. Takeuchi., J.L. Battini, R.A. Weiss, M.K. Collins (1995) High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 69: 7430-7436.
6. Cui, J., B.I. Yang, X.J. Bi, Z.R. Fan (2001) Methylation status of c-fms oncogene in HCC and its relationship with clinical pathology. World J Gastroenterol 7: 136-139.
7. Grassot, J., G. Mouchiroud, G. Perriere (2003) RTKdb: database of Receptor Tyrosine Kinase. Nucleic Acids Res 31: 353-358.
8. Griffith, J., J. Black, C. Faerman, L. Swenson, M. Wynn, F. Lu, J. Lippke, K. Saxena (2004) The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 13: 169-178.
9. Grundler, R., C. Miething, C. Thiede, C. Peschel, J. Duyster (2005) FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood 105: 4792-4799.
10. Heinrich, M.C., C.L. Corless, G.D. Demetri, C.D. Blanke, M. von Mehren, H. Joensuu, L.S. Mcgreevey, C.J. Chen, A.D. van den Abbeele, B.J. Druker, B. Kiese, B. Eisenberg, P.J. Roberts, S. Singer, C.D. Fletcher, S. Silberman, S. Dimitrijevic, J.A. Fletcher (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342-4349.
11. Heldin, C.H. (1995) Dimerization of cell surface receptors in signal transduction. Cell 80: 213-223.
12. Huse, M., J. Kuriyan (2002) The conformational plasticity of protein kinases. Cell 109: 275-282.
13. Kacinski, B.M., K.A. Scata, D. Carter, L.D. Yee, E. Sapi, B.L. King, S.K. Chambers, M.A. Jones, M.H. Pirro, E.R. Stanley, et al. (1991) FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. Oncogene 6: 941-952.
14. Kirma, N., L.S. Hammes, Y.G. Liu, H.B. Nair, P. T. Valente,S. Kumar, L.C. Flowers,R.R. Tekmal (2007) Elevated expression of the oncogene c-fms and its ligand, the macrophage colony-stimulating factor-1, in cervical cancer and the role of transforming growth factor-beta1 in inducing c-fms expression. Cancer Res 67: 1918-1926.
15. Kitzberger, R., C. Madl, P. Ferenci (2005) Wilson disease. Metab Brain Dis 20: 295-302.
16. Kiyoi, H., R. Ohno, R. Ueda, H. Saito, T. Naoe (2002) Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 21: 2555-2563.
17. Kumabe, T., Y. Sohma, T. Kayama, T. Yoshimoto, T. Yamamoto (1992) Overexpression and amplification of α-PDGF receptor gene lacking exons coding for a portion of the extracellular region in a malignant glioma. Tohoku J Exp Med 168: 265-269.
18. Longley, B.J., L. Tyrrell, S.Z. Lu, Y.S. Ma, K. Langley, T.G. Ding, T. Duffy, P. Jacobs, L.H. Tang, I. Modlin (1996) Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 12: 312-314.
19. Maroc, N., R. Rottapel, O. Rosnet, S. Marchetto, C. Lavezzi, P. Mannoni, D. Birnbaum, P. Dubreuil (1993) Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase. Oncogene 8: 909-918.
20. Miettinen, M., J. Lasota (2001) Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 438: 1-12.
21. Miyashita, T. (2004) Confocal microscopy for intracellular co-localization of proteins. Methods Mol Biol 261: 399-410.
22. Mol, C.D., D.R. Dougan, T.R. Schneider, R.J. Skene, M.L. Kraus, D.D. Scheibe, G.P. Snell, H. Zou, B.C. Sang, K.P. Wilson (2004) Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279: 31655-31663.
23. Nagata, H., A.S. Worobec, C.K. Oh, B.A. Chowdhury, S. Tannenbaum, Y. Suzuki, D.D. Metcalfe (1995) Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 92: 10560-10564.
24. Riviere, I., K. Brose, R.C. Mulligan (1995) Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA 92: 6733-6737.
25. Robinson, D.R., Y.M. Wu, S.F. Lin (2000) The protein tyrosine kinase family of the human genome. Oncogene 19: 5548-5557.
26. Rosnet, O., D. Birnbaum (1993) Hematopoietic receptors of class III receptor-type tyrosine kinases. Crit Rev Oncog 4: 595-613.
27. Rubin, B.P., S. Singer, C. Tsao, A. Duensing, M. L. Lux, R. Ruiz, M.K. Hibbard, C.J. Chen, S. Xiao, D.A. Tuveson, G.D. Demetri, C.D. Fletcher, J.A. Fletcher (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61: 8118-8121.
28. Schmidt-Arras, D.E., A. Bohmer, B. Markova, C. Choudhary, H. Serve, F.D. Bohmer (2005) Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases. Mol Cell Biol 25: 3690-3703.
29. Schülein, R. (2004) The early stages of the intracellular transport of membrane proteins: clinical and pharmacological implications. Rev Physiol Biochem Pharmacol 151: 45-91.
30. Tang, R.P., B. Kacinski, P. Validire, F. Beuvon, X. Sastre, P. Benoit, A. Dela Rochefordiere, V. Mosseri, P. Pouillart, S. Scholl (1990) Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells? J Cell Biochem 44: 189-198.
31. Tobal, K., A. Pagliuca, B. Bhatt, N. Bailey, D.M. Layton, G.J. Mufti (1990) Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 4: 486-489.
32. Turner, A.M., N.L. Lin, S. Issarachai, S.D. Lyman, V.C. Broudy (1996) FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood 88: 3383-3390.
33. Van der Geer, P., T. Hunter, R.A. Lindberg (1994) Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 10: 251-337.
34. Walter, M., I.S. Lucet, O. Patel, S.E. Broughton, R. Bamert, N.K. Williams, E. Fantino, A.F. Wilks, J. Rossjohn (2007) The 2.7 A crystal structure of the autoinhibited human c-Fms kinase domain. J Mol Biol 367: 839-847.
35. Watson, P., A.K. Townley, P. Koka, K.J. Palmer, D.J. Stephens (2006) Sec16 defines endoplasmic reticulum exit sites and is required for secretory cargo export in mammalian cells. Traffic 7: 1678-1687.
36. Xiang, Z.,F. Kreisel, J. Cain, A. Colson, M.H. Tomasson (2007) Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signalling. Mol Cell Biol 27: 267-282.
37. Yamamoto, Y., H. Kiyoi, Y. Nakano, R. Suzuki, Y. Kodera, S. Miyawaki, N. Asou, K. Kuriyama, F. Yagasaki, C. Shimazaki, H. Akiyama, K. Saito, M. Nishimura, T. Motoji, K. Shinagawa, A. Takeshita, H. Saito, R. Ueda, R. Ohno, T. Naoe (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97: 2434-2439.
38. Yang, D.H., W. Huang, J. CUI, K.C. Shu, S.H. Tang, W.J. Zhang, J.H. Liang (2004) The relationship between point mutation and abnormal expression of c-fms oncogene in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 3: 86-89.